PRME News and Press, First Trust Heitman Global Prime Real Estate ETF From 11/03/25

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer ...

CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that it will host a virtual event on Wednesday, November 12, 2025, to discuss...

2025-09-23 11:36:29 ET Prime Medicine, Inc. ( PRME ) stock is having a great month with double-digit gains, a momentum it has carried for the past three months with gains now in three digits, over 130%. The company is gaining renewed visibility following its presentation las...

2025-09-08 17:38:01 ET Prime Medicine, Inc. (PRME) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 1:05 PM EDT... Read the full article on Seeking Alpha For further details see: Prime Medicine, Inc. (PRME) Presents At Morgan Stanley 23rd Annual Glob...

2025-09-02 20:07:15 ET Prime Medicine, Inc. (PRME) Citi's Biopharma Back to School Conference September 2, 2025 4:45 PM EDT... Read the full article on Seeking Alpha For further details see: Prime Medicine, Inc. (PRME) Presents At Citi's Biopharma Back To School Conference T...

Prime Medicine Inc. (PRME) is expected to report $-0.36 for Q2 2025

2025-08-07 08:29:52 ET More on Prime Medicine Prime Medicine: Pressing Forward With Lead Liver Targeting Indications Prime Medicine slides after pricing $125.4M stock offering Prime Medicine soars as Jones sees it as an acquisition target Seeking Alpha’...

-- Announced positive data from two patients in Phase 1/2 clinical trial in Chronic Granulomatous Disease (CGD), providing clinical proof-of-concept for Prime Editing; plan to have regulatory interactions based on current dataset -- -- Completed follow-on offering, raising $144.2 million ...

CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its underwritten public offering of 43,700,000 shares of its c...

2025-07-30 23:51:21 ET More on Prime Medicine Prime Medicine: Pressing Forward With Lead Liver Targeting Indications Prime Medicine soars as Jones sees it as an acquisition target RFK Jr. looks to fast track rare disease drug approvals (updated) Seeking Alpha...